CureVac's prostate cancer vaccine fails in Phase IIb trial

CureVac AG (Tuebingen, Germany) said its lead vaccine candidate CV9104 failed to improve overall survival in a Phase IIb study to treat castration-resistant prostate cancer (CRPC), missing its primary endpoint. The company presented the results on Wednesday at the JPMorgan Healthcare Conference in San Francisco.

CureVac also said progression-free survival, a secondary endpoint, was similar in the trial's two arms comparing CV9104 with placebo. The study enrolled 197 patients with asymptomatic or minimally symptomatic metastatic CRPC. CureVac said it will release full results at an upcoming medical meeting...